Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TJ210001 in advanced solid tumors
NCT04678921Phase 1Completed
- Sponsor
- I-Mab
- Start
- Dec 2020
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of izastobart in solid tumor (4 arms), sponsored by I-Mab. Primary endpoints: Incidence and Severity of Adverse Events and Maximum Tolerated Dose at 21 days. Started Dec 2020; status: completed.
02
Drugs
izastobart
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04678921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04678921.